Relationship Between the Clinical Pharmacist & Antibiotic Use by Using the Electronic Program

Relationship Between the Clinical Pharmacist & Antibiotic Use in Selected Infectious Disease Hospitals in El Beheira by Using the Electronic Program, Retrospective Cohort

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05002647

Enrollment

2601

Registered

2021-08-12

Start date

2021-09-15

Completion date

2022-03-10

Last updated

2024-12-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinical Pharmacists, Electronic Medical Record

Keywords

clinical pharmacist, antibiotic consumption, antibiotic use, cost-saving

Brief summary

A retrospective cohort study to explore the association between clinical pharmacists' interventions and antibiotic consumption through the use of the medical electronic reports and to identify mortality and cost savings in hospital infectious disease.

Detailed description

The role of clinical pharmacist includes : 1. a check of suitable selection and dosing of antimicrobials according to the diagnosis, type of infection, antimicrobial cultures as possible, comorbidities of patients (renal or hepatic function, etc), adverse effect, and drug interaction with other drugs. 2. Documentation of the clinical intervention, cost-saving, adverse effect,, antimicrobial culture and antimicrobial consumption on the electronic program (CPC clinical patient care). 3. The clinical pharmacist inspector reviews the data recorded on CPC.

Interventions

OTHERNO intervention

There is no intervention

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* All inpatient with infectious disease (disorders caused by organisms as (bacteria, viruses, fungi, or parasites).

Exclusion criteria

* Any other cause of hospital admission other than infectious disease.

Design outcomes

Primary

Measure	Time frame	Description
Antimicrobial consumption	2 years	consumption of antimicrobials (defined daily doses / 100 patient-days)
Days of therapy (DOT)	2 years	Number of days of each antimicrobial received for therapy
Length of therapy(LOT)	2 years	The number of days a patient takes an antibacterial drug, regardless of the number of different medications

Secondary

Measure	Time frame	Description
Mortality rate	2 years	in-hospital mortality rate (%)
The incidence of adverse reaction of antimicrobial	2 years	An unexpected medical problem that happens during treatment with antimicrobial.
cost savings	2 years	(initial treatment cost × days before intervention) - (cost after intervention × days with this treatment),
Antimicrobial resistance	2 years	resistance defined as resistance to at least one antimicrobial from the panel for all organisms, and for a subset of organisms belonging to the ESKAPE group (Enterococcus faecium, S. aureus, Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa , and Enterobacter spp.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026